Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $10.01M | $25.55M | $1.38M | $3.03M | $82.65M | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | $3.55M | $2.85M | $2.15M |
| Gross Profit | $10.01M | $25.55M | $1.38M | $3.03M | $79.11M | $-2.85M | $-2.15M |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 95.71% | 0.00% | 0.00% |
| Operating Expenses | $382.48M | $398.55M | $300.66M | $367.73M | $134.90M | $81.20M | $47.73M |
| Operating Income | $-372.47M | $-373.00M | $-299.27M | $-364.70M | $-55.80M | $-84.05M | $-49.89M |
| Operating Margin | -3722.07% | -1460.11% | -21670.89% | -12040.21% | -67.51% | 0.00% | 0.00% |
| Net Income | $-337.71M | $-341.97M | $-290.51M | $-363.87M | $-52.41M | $-66.50M | $-48.78M |
| Net Margin | -3374.72% | -1338.66% | -21036.13% | -12012.94% | -63.41% | 0.00% | 0.00% |
| EPS (Basic) | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-2.56 | $-15.53 | $-19.63 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |